Semaglutide: the medication, the brands and the prices
Semaglutide is a once-weekly GLP-1 receptor agonist, FDA-approved as Wegovy (weight management; pen, HD pen and pill), Ozempic and Rybelsus (type 2 diabetes). As of November 20, 2026, compounded semaglutide costs $75.58 to $299 per billing cycle month to month, all-in, at the programs we track that print a comparable price; brand Wegovy pens cost $349 a month bought direct.
Released · Last reviewed · how we verify
Compounded semaglutide prices, November 20, 2026
| Program | Month to month, all-in | Billing basis | Year at that price | Lowest printed rate | Dose pricing | Read |
|---|---|---|---|---|---|---|
| Collective | $75.58 | per month | $907 | $75.58 ($59 a month plus $199 a year) | same at every dose | 2026-11-20 |
| Mondae | $87 | per month | $1,044 | $69 (6-month plan, $414) | same at every dose | 2026-11-20 |
| Yucca Health | $89 | per month | $1,068 | $69 (12-month plan, $828 upfront) | same at every dose | 2026-11-20 |
| Eden | $99 | per month | $1,188 | $99 (every month) | same at every dose | 2026-11-20 |
| NexLife | $109 | per month | $1,308 | $95 (12-month plan) | same at every dose | 2026-11-20 |
| OrderlyMeds | $149 | per month | $1,788 | $74 (2-month new-customer offer, $149) | same at every dose | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $199 (4-week program) | not stated as flat | 2026-11-20 |
| Noom Med | $249 | per 28-day cycle | $3,237 | $249 (per 4 weeks, billed every 12 weeks) | not stated as flat | 2026-11-20 |
| Found | $269 | per 28-day cycle | $3,497 | $149 (12-month term, per 28-day cycle) | not stated as flat | 2026-11-20 |
| Henry Meds | $297 | per month | $3,564 | $197 (12 months paid in full, $2,364) | not stated as flat | 2026-11-20 |
| Remedy Meds | $299 | per 28-day cycle | $3,887 | $299 (4-week supply; $179 first month only) | same at every dose | 2026-11-20 |
Starting-dose, coupon or “from” prices only (read November 20, 2026; not comparable like for like): IVIM Health: $140 a month at the starting dose ($65 medication plus a $75 monthly program fee); ShedRx: from $159 ("GLP-1s from $159/mo" (drug not named)), no month-to-month price printed; Mochi Health: $139 a month at the starting dose ($60 starting-dose medication plus a $79 monthly membership); Lavender Sky Health: $135 a month at the starting dose (one-month starter supply; priced by dose and pharmacy); Fridays: from $69 (with a coupon code), no month-to-month price printed; Big Easy Weight Loss: from $133 ($399 per 12 weeks), no month-to-month price printed; Goby Meds: $169 a month at the starting dose (single month at the lowest dose; priced by dose).
No current price shown: SkinnyRx (only a $99 first-month offer was visible); Amble Health (only "plans starting at $99", drug not named); TrimRx (page not readable); MEDVi (prices did not render); Oak Longevity (only "from $109", drug not named); Enhance.MD (semaglutide not in the re-read); bmiMD (page refused automated reads); Emerge Weight Loss (no semaglutide price printed); Embody (page not readable); Rift (not re-read); Gimme Care (not re-read); Trillium (not re-read); MyStart Health (not re-read); Gala Health (not re-read). These records show no figure rather than an older one presented as current.
Brand prices
| Medication | Dose | Self-pay price | Condition |
|---|---|---|---|
| Zepbound vial (LillyDirect) | 2.5 mg | $299 | per fill |
| Zepbound vial (LillyDirect) | 5 mg | $399 | per fill |
| Zepbound vial (LillyDirect) | 7.5–15 mg | $449 | each refill within 45 days; otherwise $499 (7.5 mg) or $699 (10–15 mg) |
| Wegovy pen (NovoCare) | 0.25–2.4 mg | $349 | new patients: $199 for each of the first two fills of 0.25 or 0.5 mg through December 31, 2026 |
| Wegovy HD pen (NovoCare) | 7.2 mg | $399 | per month |
| Wegovy pill (NovoCare) | 1.5 / 4 / 9 and 25 mg | $149 / $199 / $299 | per month |
| Foundayo (LillyDirect) | from 0.8 mg | from $149 | 2.5 and 5.5 mg temporarily reduced through December 31, 2026 |
What the trials show
In STEP 1, semaglutide 2.4 mg produced 14.9% average weight loss against 2.4% on placebo at 68 weeks, and in SELECT it lowered major cardiovascular events by 20% in adults with heart disease and no diabetes. In SURMOUNT-5, semaglutide produced 13.7% against 20.2% for tirzepatide. These results belong to the approved drug, not to compounded versions.
Compounded semaglutide: the legal lane
Compounded semaglutide is not FDA-approved and is not the same product as Wegovy. It is prescribed for an individual patient and filled by a state-licensed 503A pharmacy. FDA proposed on April 30, 2026 not to allow 503B outsourcing facilities to compound it from bulk; no final decision was found as of November 20, 2026. On November 9, 2026, FDA required a warning about NAION, a rare optic-nerve condition, on the labels of approved GLP-1 drugs.
Frequently asked
What does semaglutide cost in November 2026?
Semaglutide is a once-weekly GLP-1 receptor agonist, FDA-approved as Wegovy (weight management; pen, HD pen and pill), Ozempic and Rybelsus (type 2 diabetes). As of November 20, 2026, compounded semaglutide costs $75.58 to $299 per billing cycle month to month, all-in, at the programs we track that print a comparable price; brand Wegovy pens cost $349 a month bought direct.
How much does compounded semaglutide cost online in November 2026?
As of November 20, 2026, compounded semaglutide costs $75.58 to $299 per billing cycle month to month, all-in, across the 11 programs in our dataset that print a price applying at every dose or at the maintenance dose, which is $907 to $3,887 for a year (median $1,788). Price check, month to month: Collective about $75.58 all-in, Mondae $87, Yucca Health $89, Eden $99 and NexLife $109, or $95 a month on its 12-month plan. Brand Wegovy pens cost $349 a month through NovoCare.
Are compounded tirzepatide and semaglutide legal and FDA-approved in 2026?
Compounded tirzepatide and semaglutide are not FDA-approved, and as of November 20, 2026 they reach U.S. patients as prescriptions for an individual patient filled by state-licensed 503A compounding pharmacies; they are made with the drug in Zepbound or Wegovy but are not the same product. FDA proposed on April 30, 2026 not to place either drug on the 503B bulks list, and no final decision was found as of November 20. Warning letters continue, including letter 737905 to telehealth seller RonanRx on October 30, 2026.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- FDA Drug Safety Communication: safety labeling changes for GLP-1 receptor agonists (NAION) (November 9, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- NovoCare Pharmacy: Wegovy self-pay prices (read November 20, 2026)